Functional Compromise Cohort Study (FCCS): Sarcopenia is a Strong Predictor of Mortality in the Intensive Care Unit

Hoogt, Patrick A. de; Reisinger, Kostan W.; Tegels, Juul J. W.; Bosmans, Joanna W. A. M.; Tijssen, Fabian H.; Stoot, Jan H.M.B.

doi:10.1007/s00268-017-4386-8

Cited by 40 publications

(34 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Once sarcopenia suspected, it should be diagnosed early, and supportive treatment should be started immediately. (14). As in our patient, sepsis is a risk factor for prolonged ventilator and acquired neuromuscular weakness, which may be a common problem of patientsin ICU (15).…”

Section: Discussionmentioning

confidence: 58%

Case report presentation of emerging seconder sarcopenia after sepsis attacks in intensive care unit

Çakır¹,

Akan²,

Sarı³

et al. 2019

tjgeri

View full text Add to dashboard Cite

Sarcopenia is defined as decreased muscle mass, muscle strength and physical performance. In geriatric patients, secondary sarcopenia may also develop due to underlying diseases in addition to the known primary sarcopenia. Computed tomography and magnetic resonance imaging are the gold standard to calculate skeletal muscle index in the diagnosis of sarcopenia. The diagnostic approach is easier in mobilized, outpatient and hospitalized patient. However, it is difficult to perform a gold standard computed tomography and magnetic resonance imaging for the diagnosis of sarcopenia and evaluate muscle strength and physical performance in patients who cannot be mobilized and stay in the intensive care unit. In this case report, we aimed to present the case in order to raise the awareness of clinicians considering the difficulty of application of diagnostic criteria of secondary sarcopenia in the course of prolonged intensive care unit hospitalization and difficulty of performing computed tomography and the lack of consensus on prevention and treatment of sarcopenia.

show abstract

Section: Discussionmentioning

confidence: 58%

Case report presentation of emerging seconder sarcopenia after sepsis attacks in intensive care unit

Çakır¹,

Akan²,

Sarı³

et al. 2019

tjgeri

View full text Add to dashboard Cite

show abstract

“…Age-related chronic low-grade inflammation may be an important contributor to sarcopenia [6,88,93]. Sarcopenia seems to increase the likelihood of adverse outcomes such as disability, poor quality of life and death [101][102][103]. Both muscle mass and strength were predictive for difficulties in performing activities of daily living after discharge from the hospital [104].…”

Section: Omega-3 Lcpufas and Sarcopenia And Frailty In Older Peoplementioning

confidence: 99%

Expert Opinion on Benefits of Long-Chain Omega-3 Fatty Acids (DHA and EPA) in Aging and Clinical Nutrition

et al. 2020

View full text Add to dashboard Cite

Life expectancy is increasing and so is the prevalence of age-related non-communicable diseases (NCDs). Consequently, older people and patients present with multi-morbidities and more complex needs, putting significant pressure on healthcare systems. Effective nutrition interventions could be an important tool to address patient needs, improve clinical outcomes and reduce healthcare costs. Inflammation plays a central role in NCDs, so targeting it is relevant to disease prevention and treatment. The long-chain omega-3 polyunsaturated fatty acids (omega-3 LCPUFAs) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are known to reduce inflammation and promote its resolution, suggesting a beneficial role in various therapeutic areas. An expert group reviewed the data on omega-3 LCPUFAs in specific patient populations and medical conditions. Evidence for benefits in cognitive health, age- and disease-related decline in muscle mass, cancer treatment, surgical patients and critical illness was identified. Use of DHA and EPA in some conditions is already included in some relevant guidelines. However, it is important to note that data on the effects of omega-3 LCPUFAs are still inconsistent in many areas (e.g., cognitive decline) due to a range of factors that vary amongst the trials performed to date; these factors include dose, timing and duration; baseline omega-3 LCPUFA status; and intake of other nutrients. Well-designed intervention studies are required to optimize the effects of DHA and EPA in specific patient populations and to develop more personalized strategies for their use.

show abstract

“…All of the studies that were included were retrospective cohort studies, with the exception of one 34 , which was a prospective cohort study. A total of ve studies was conducted in the U.S. 10,23,24,33,34 ; while China 21,22 , Japan 17,35 , and the Netherlands 11,18 each had two studies, and Korea 20 , Australia 25 , and Brazil 19 each had one study respectively. All studies used CT to detect sarcopenia.…”

Section: Study Summarymentioning

confidence: 99%

Sarcopenia as A Predictor of Mortality Among the Critically Ill in an Intensive Care Unit: A Systematic Review and Meta-Analysis

Zhang

Chen

Xie

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The evidence of sarcopenia based on CT-scan as an important prognostic factor for critically ill patients has not seen consistent results. Objective: To determine the impact of sarcopenia on mortality in critically ill patients, we performed a systematic review and meta-analysis to quantify the association between sarcopenia and mortality.Methods: We searched studies from the literature of PubMed, EMBASE, and Cochrane Library from database inception to June 15, 2020. All observational studies exploring the relationship between sarcopenia based on CT-scan and mortality in critically ill patients were included. The search and data analysis were independently conducted by two investigators. A meta-analysis was performed using STATA Version 14.0 software using a fixed effects mode. Results: Fourteen studies with a total of 3,249 participants were included in our meta-analysis. The pooled prevalence of sarcopenia among critically ill patients was 38% (95% CI:36%-39%). Critically ill patients with sarcopenia in intensive care unit have an increased risk of mortality, compared to critically ill patients without sarcopenia (HR=2.22, 95%CI: 1.79-2.75; P<0.001; I2=0.0%). In addition, a subgroup analysis found a significant difference in the association between sarcopenia and mortality when using total psoas muscle area (TPA), skeletal muscle index (SMI), and skeletal muscle area (SMA) to define sarcopenia (HR=2.96,95%CI:1.72-5.11,P<0.001; HR = 2.11,95%CI:1.59-2.80,P<0.01; HR=2.11, 95%CI:1.33-3.33,P=0.001, respectively), whereas the results were not significant when measuring the masseter muscle to define sarcopenia (HR=2.00, 95%CI:0.82-4.90,P=0.129).Conclusion: Sarcopenia increases the risk of mortality in critical illness. Identifying the risk factors of sarcopenia should be routine in clinical assessments, offering corresponding interventions may help medical staff achieve good patient outcomes in ICU departments.

show abstract

Functional Compromise Cohort Study (FCCS): Sarcopenia is a Strong Predictor of Mortality in the Intensive Care Unit

Cited by 40 publications

References 35 publications

Case report presentation of emerging seconder sarcopenia after sepsis attacks in intensive care unit

Case report presentation of emerging seconder sarcopenia after sepsis attacks in intensive care unit

Expert Opinion on Benefits of Long-Chain Omega-3 Fatty Acids (DHA and EPA) in Aging and Clinical Nutrition

Sarcopenia as A Predictor of Mortality Among the Critically Ill in an Intensive Care Unit: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About